‘NeoGenomics to Appeal Court Ruling on RaDaR Technology Patent Infringement\n\nThe S&P 500 came within inches of a record high on Thursday, but ultimately settled for a small gain as the stock market faded and small caps underperformed. The S&P 500 saw a slight increase of less than 0.1%, while the Nasdaq composite closed slightly lower after erasing earlier gains.\n\nNeoGenomics (NASDAQ:NEO), a leading oncology testing services company, announced today that its subsidiary, NeoGenomics Laboratories, incorporated, will appeal a preliminary injunction issued by the United States District Court for the Middle District of North Carolina. The injunction was issued after Natera, incorporated claimed that NeoGenomics’ RaDaR technology infringes on one of its patents. The court’s order allows patients currently using RaDaR to continue their treatment, as well as ongoing research projects and clinical trials.\n\nIn response to the ruling, NeoGenomics’ CEO Chris Smith stated, “We remain confident in the innovative and distinguished technology of RaDaR and plan to appeal the court’s decision. Our focus remains on bringing this highly sensitive test to market and providing cancer patients and their clinicians with more options for their care.”\n\nNeoGenomics, incorporated specializes in cancer genetics testing and information services, offering one of the most comprehensive oncology-focused testing menus for physicians. The company’s Advanced Diagnostic Division also serves pharmaceutical clients in clinical trials and drug development. With laboratories in multiple locations across the United States and Europe, NeoGenomics serves the needs of pathologists, oncologists, and other healthcare organizations.\n\nNeoGenomics, incorporated plans to appeal the court’s ruling on RaDaR technology patent infringement, while continuing to focus on providing innovative and comprehensive testing options for cancer patients.’